Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ctDNA-guided Cadonilimab in Cervical Cancer
NCT06878196Phase 2Not yet recruiting
- Sponsor
- Obstetrics and Gynecology Hospital of Fudan University
- Start
- Mar 2025
- Primary completion
- Dec 2028
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of cadonilimab in Cervical Cancer (CC), sponsored by Obstetrics and Gynecology Hospital of Fudan University. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
cadonilimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT06878196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06878196.